FDA post-marketing powers dropped

An amendment that would give FDA the authority to mandate post-market drug safety studies was dropped from the House Agriculture Appropriations bill May 23. The amendment violated a rule prohibiting legislation in appropriation bills, Energy & Commerce/Health Subcommittee Chairman Nathan Deal (R-Ga.) pointed out during same-day floor debate. The bill retained several other amendments that were added during committee including a provision that would limit FDA's ability to grant conflict-of-interest waivers for members of advisory committees. The appropriations measure passed the House by a 378 to 46 vote...